Evotec SE and Takeda Pharmaceutical Company Ltd have entered a strategic drug discovery collaboration potentially worth $850m.
Under the agreement, Evotec will develop at least five small molecule discovery programmes against targets identified by Takeda in oncology, gastroenterology, neuroscience and rare diseases. Takeda will have the option to assume responsibility at lead series and upon Evotec delivering a pre-clinical candidate.
Under the terms of the collaboration, Takeda will pay Evotec an undiclosed upfront fee to get access to its platforms. Additionally, Evotec is eligible to receive pre-clinical, clinical, and commercial milestones that can total in excess of $170 m per programme as well as tiered royalties on future sales.

Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and  metabolism of the malaria parasite Plasmodium falciparum.

Danish Lundbeck AS is has secured a stake in the  migraine market by paying US$1.95bn (€1.76bn) to acquire Alder BioPharmaceuticals Inc. 

German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.

Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.